Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


MRI and thallium-201 SPECT in the prediction of survival in glioma.

Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske DP, Postma TJ.

Neuroradiology. 2012 Jun;54(6):539-46. doi: 10.1007/s00234-011-0908-5. Epub 2011 Jul 14.


Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.

Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen CJ, Vandertop WP, Slotman BJ, Postma TJ.

J Clin Oncol. 2003 Oct 1;21(19):3559-65. Epub 2003 Aug 11.


Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

Perry JR, BĂ©langer K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF.

J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.


Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.


Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.


The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.

J Neurooncol. 2008 May;88(1):43-50. doi: 10.1007/s11060-008-9530-8. Epub 2008 Jan 30.


Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.


The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.


Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.


Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.

Kim WH, Yoon SH, Kim CY, Kim KJ, Lee MM, Choe G, Kim IA, Kim JH, Kim YJ, Kim HJ.

J Neurooncol. 2011 Jan;101(2):247-54. doi: 10.1007/s11060-010-0249-y. Epub 2010 Jun 5. Review. Erratum in: J Neurooncol. 2011 Jan;101(2):255. Kim, Wook-Ha [corrected to Kim, Wook Ha].


Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.

Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, Sarin R, Kurkure P.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113-8. doi: 10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3.


Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.

Jung TY, Kim CY, Kim DS, Ra YS, Kim SH, Baek HJ, Choi HS, Kim IA.

Childs Nerv Syst. 2012 Jul;28(7):1033-9. doi: 10.1007/s00381-012-1786-9. Epub 2012 May 11.


Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.


Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.

Yang P, Zhang C, Cai J, You G, Wang Y, Qiu X, Li S, Wu C, Yao K, Li W, Peng X, Zhang W, Jiang T.

Oncotarget. 2016 Nov 29;7(48):80091-80100. doi: 10.18632/oncotarget.11756.


Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.

Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

PLoS One. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587. eCollection 2014.


Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.


When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.

Huang F, Kavan P, Guiot MC, Markovic Y, Roberge D.

Can J Neurol Sci. 2008 May;35(2):192-7.


Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.

Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ.

J Neurooncol. 2016 Jan;126(2):347-54. doi: 10.1007/s11060-015-1975-y. Epub 2015 Nov 7.

Supplemental Content

Support Center